New Horizons in the Treatment and Management of Lymphoma: Novel Therapies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 30, 2018 to June 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from Bayer Healthcare and Merck & Co.

Description:
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma (NHL) in the Western Hemisphere. No sex preponderance is seen for follicular lymphomas, but the incidence increases with age and varies across racial groups. With current therapy options, prognosis is favorable, with median overall survival (OS) exceeding 12 years. There are various treatment options for FL based on the severity of associated symptoms and the rate of cancer growth. Active treatment is started if the patient begins to develop lymphoma-related symptoms or there are signs that the disease is progressing based on testing during follow- up visits. After treatment, many patients can go into a remission that lasts for years; however, this disease should be considered a lifelong condition as relapsed disease can occur. Recent advances in disease management and our understanding of the biology of FL have led to a dramatic change in the treatment landscape. Despite this progress, FL remains incurable with standard therapies but fortunately for patients with FL, several new agents have become available in the past year, including targeted therapy. They have shown the ability to improve safety and efficacy outcomes, especially in patients with relapsed disease that have had other therapies.

Upon Completion of this activity, participants will be able to:

  • Examine efficacy and safety profiles of novel targeted agents in the treatment of relapsed follicular lymphoma (FL)

  • Analyze the role of immunotherapies in the treatment of refractory or relapsed Hodgkin Lymphoma (HL)

  • Review the clinical trial data for novel agents for the treatment of relapsed/refractory follicular lymphoma or hodgkin lymphoma

  • Define the risks and adverse events associated with targeted agents or immunotherapies indicated for the treatment of patients with lymphomas in order to maximize tolerability and adherence to therapeutic regimens
     

Faculty: Matthew S. McKinney, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine

Disclosure:

Dr. McKinney has no relevant financial relationships to disclose. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from Bayer Healthcare and Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue